Nilotinib, already used to treat leukaemia, is what is known as a tyrosine kinase inhibitor which works by blocking a protein called BCR-ABL, whose activity is uncontrolled in cancer cells and leads to cell proliferation. Previous studies have shown that this protein can accumulate in the brain and is linked to several pathways in Parkinson's such as oxidative stress and  alpha-synuclein-induced neurodegeneration.

The Cure Parkinson's Trust collaborated with The Michael J Fox Foundation and The Van Andel Research Institute through the Linked Clinical Trials initiative on the clinical development of Nilotinib toward the launch of this clinical trial. This trial is now recruiting.

Read more about this important trial here.